Doxorubicin hydrochloride liposome

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Doxorubicin hydrochloride liposome is one of 51 small molecule programs targeting Corticosteroids. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CorticosteroidsRecruiting

Ovarian CancerCompleted

CorticosteroidsPhase 3

Recruiting

Ovarian CancerPhase 1

Completed

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

33 2

Hycamtin

MMeitheal

Phase 3

26 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 5

Femara

Novartis

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

23 7

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 8

Neulasta

Amgen

Phase 3

2 9

Taxotere

AAvyxa

Phase 3

11 10

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Ovarian Cancer

NCT06840002

Q1 2027

Phase 3Recruiting

Corticosteroids

NCT07362914

Q4 2027

Phase 3Recruiting

Ovarian Cancer

NCT06828354

Q4 2028

PreclinicalNot yet recruiting

Diffuse Large B-Cell Lymphoma

NCT07818499

Phase 2Active, not recruiting

Breast Cancer

NCT04872985

Clinical

Trials by Indication[1]

Ovarian Cancer4 trials

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

Completed·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 1·NCT02237690·30 enrolled

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06828354·300 enrolled

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Completed·AAyana Pharma Ltd.,·Phase 1·NCT03681548·52 enrolled

Show 1 more trial

An Open, Multicenter Phase Ib / II Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Preclinical·NCT06840002·150 enrolled

Breast Cancer3 trials

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Completed· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 1·NCT06098599·48 enrolled

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04872985·140 enrolled

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Completed·HHebei Medical University Fourth Hospital·N/A·NCT03017404·18 enrolled

Doxorubicin3 trials

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Completed·—·Phase 1·NCT02260544·49 enrolled

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Unknown status·SShenzhen Kangzhe Pharmaceutical Co., Ltd.·Phase 1·NCT05273944·80 enrolled

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·N/A·NCT04460820·32 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT04983550·126 enrolled

Treatment1 trial

L-DEP as an Initial Treatment for EBV-HLH

Unknown status·—·Phase 3·NCT02912702·120 enrolled

4 more indications

Liposomal Doxorubicin1 trial

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Unknown status·FFudan University·Phase 2·NCT05354076·30 enrolled

Induction Therapy1 trial

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00632827·21 enrolled

Corticosteroids1 trial

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

Recruiting·FFudan University·Phase 3·NCT07362914·182 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of BL-M08D1 for Injection in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07818499·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Doxorubicin hydrochloride liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxorubicin hydrochloride liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxorubicin hydrochloride liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Doxorubicin hydrochloride liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Ovarian Cancer4 trials

Breast Cancer3 trials

Doxorubicin3 trials

Efficacy and Safety1 trial

Treatment1 trial

Liposomal Doxorubicin1 trial

Induction Therapy1 trial

Corticosteroids1 trial

Diffuse Large B-Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News